Mad Money with Jim Cramer - MAD CAP RECAP - The Official Mad Money Blog
RSS FEED
RECENT POSTS
- Lightning Round: Akorn, UnitedHealth, Stillwater Mining and More
- Herbalife Shares Gain on Obesity Play
- Allscripts CEO Talks High Tech Turnaround
- High Gas Price Hasn't Impacted Stock Market
- Waste Management CEO Talks to Cramer
- Lightning Round: R.R. Donnelley & Sons, Hanesbrands, Regeneron Pharmaceuticals and More
- Cramer: Charting Apple
- Cramer's One-on-One With EOG Resources CEO
- Cramer on Why Dow 13,000 Matters
- How to Time Your Sells
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Why Sanofi Is a Buy
Text Size 
Producer
All week, Cramer has been highlighting big pharma stocks that are poised to pop in the year to come. But the “Mad Money” host saved his fave stock for last, namely, Sanofi-Aventis [SNY
Loading...
()
].
Sanofi is the world’s largest drug company with a stock that sports a 4.8 percent dividend yield. The stock has run up by 16 percent last year, if you had reinvested dividends, but Cramer thinks it could still go higher.
Cramer likes Sanofi because three of its biggest drugs are going generic this year, but the company saw the dangers coming and took steps to make sure it never happens again. He hands it to the company’s management, who he praised for their strategic thinking and leadership.
Going forward, the company is investing in high growth platforms that are protected by more than just a patent, such as vaccines where barriers to entry are high, diabetes and generics. In doing so, the company hopes to build brand loyalty.
Cramer thinks Sanofi is a buy, buy, buy.
When this story was published, Cramer's charitable trust owned Sanofi.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes
